Indivumed and Definiens Partner to Unlock the Power of Tumor Tissue for Drug Discovery and Development

(PresseBox) ( Hamburg/Munich, )
Definiens, the pioneer in Tissue Phenomics solutions for diagnostics development and commercialization and Indivumed, GmbH, based in Hamburg, Germany announce today a strategic partnership to offer a unique combination of tissue-based biomarker validation and assay development with Definiens Cognition Network Technology® for image analysis and data mining.

This partnership will allow researchers and clinicians in oncology benefit from a joint offering of Indivumed’s leading Cancer Database, Biobank and analytical laboratory services for tissue analysis together with Definiens leading proprietary Cognition Network Technology® and the Tissue Phenomics® approach to oncology and diagnostics. Indivumed specializes in stringent and highly standardized tissue collection process that preserve biomolecules such as RNA and protein, allowing more accurate assessment of tissue patterns and more rigorous comparisons across samples.

“Customers of either company can now benefit from this partnership and our comprehensive approach for image analysis and tissue-based research and development in oncology” said Hartmut Juhl, Founder and Chief Executive Officer of Indivumed.

“In the quest to use tissue biomarkers to create diagnostic tests for cancer patients, there is no question that the quality of tissue combined with advanced image analysis and tissue mining is extremely important,” commented Ralf Huss, Chief Medical Officer for Definiens. “This partnership allows researchers and clinicians to benefit from the expertise of both our companies and advance personalized medicine for treatment of patients. It will be great to see this partnership benefit not only researchers and clinicians, but also ultimately cancer patients.”

About Definiens

Definiens is the pioneering provider of Tissue Phenomics® solutions for biomarker and companion diagnostics development and commercialization. Definiens’ technology empowers smarter tissue-based diagnostics by leveraging quantitative tissue readouts and other big data sources. By enabling the development of powerful and precise assays for patient stratification and clinical trial enrollment, Definiens aims to dramatically improve patient outcomes. Definiens' Tissue Phenomics approach was awarded the 2013 Frost and Sullivan Company of the Year Award for Global Tissue Diagnostics and Pathology Imaging.

For more information, please visit: www.definiens.com 

 
The publisher indicated in each case is solely responsible for the press releases above, the event or job offer displayed, and the image and sound material used (see company info when clicking on image/message title or company info right column). As a rule, the publisher is also the author of the press releases and the attached image, sound and information material.
The use of information published here for personal information and editorial processing is generally free of charge. Please clarify any copyright issues with the stated publisher before further use. In the event of publication, please send a specimen copy to service@pressebox.de.